Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates
- 1 March 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (3) , 1067-1073
- https://doi.org/10.1128/aac.00860-08
Abstract
The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets—two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h−1(61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters·h−1, and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg·liter−1·h and 1.68 and 0.076 mg/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg·liter−1. We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.Keywords
This publication has 16 references indexed in Scilit:
- Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometryJournal of Chromatography B, 2008
- Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trialThe Lancet, 2007
- Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy VolunteersThe Journal of Clinical Pharmacology, 2007
- Nevirapine (NVP) Resistance in Women with HIV‐1 Subtype C, Compared with Subtypes A and D, after the Administration of Single‐Dose NVPThe Journal of Infectious Diseases, 2005
- Ways to Fit a PK Model with Some Data Below the Quantification LimitJournal of Pharmacokinetics and Pharmacodynamics, 2001
- Antiretroviral Pharmacology in Pregnant Women and Their NewbornsAnnals of the New York Academy of Sciences, 2000
- Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmissionAIDS, 2000
- Pharmacokinetic Changes During Pregnancy and Their Clinical RelevanceClinical Pharmacokinetics, 1997
- R: A Language for Data Analysis and GraphicsJournal of Computational and Graphical Statistics, 1996
- Drug disposition and pharmacokinetics in the maternal-placental-fetal unitPharmacology & Therapeutics, 1980